Mikostat

Quick links to important sections

Mikostat

Treatment option: Infection, Oral Cavity

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mikostat

What is Mikostat? Identity, Class, and Purpose

Property Description
Active ingredient Nystatin (INN)
Form Oral suspension, topical cream, vaginal tablet, etc.
Pharmacological class Polyene Antifungal Antibiotic
Common use Management of localized yeast/fungal infections
Origin Natural source (from Streptomyces noursei)

The Active Ingredient and Pharmacological Class

Mikostat is a pharmaceutical preparation containing the active ingredient Nystatin (INN). Nystatin is precisely classified as a polyene macrolide antifungal antibiotic, a class of antimycotic agents effective against a wide variety of yeasts and yeast-like fungi. This classification is clinically recognized for its established role in treating localized fungal overgrowth, differentiating its function from antibacterial agents. The compound is derived from a natural source, having been historically isolated from cultures of the bacterium Streptomyces noursei. Mikostat is generally a single-ingredient product, focusing its activity solely through Nystatin. Its formulation is often tailored toward specific patient groups, such as an oral suspension for pediatric use or for those requiring localized treatment of oral candidiasis.

Mikostat’s Forms and Primary Localized Purpose

The general purpose of Mikostat is to combat and eliminate localized yeast or fungal infections, acting as an antimycotic agent against overgrowth such as that causing candidiasis. The drug is presented in several specialized pharmaceutical preparations designed exclusively for localized application, which include oral suspension, topical cream or ointment, and vaginal tablets. The route of administration is primarily topical/local, consistent with the drug’s pharmacological characteristic of being absorbed very sparingly following oral administration. This minimal systemic absorption ensures its therapeutic effect is highly concentrated at the infection site, such as the mucous membranes or skin. For instance, the oral suspension form is specifically positioned to treat superficial infections within the mouth and throat, leveraging its localized effect to control the fungal overgrowth and resolve the associated local symptoms.

Regulatory References

  1. MedlinePlus Nystatin Information
  2. DailyMed NIH

What side effects are possible with Mikostat?

Possible Side Effects and Safety Information

The safety profile of Mikostat is primarily based on officially documented adverse reactions from clinical studies and post-marketing surveillance. This section summarizes the common and serious safety concerns as stated in authoritative government regulatory documents.

Adverse Reactions by System and Frequency

Common adverse reactions documented include diarrhea, nausea, vomiting, and stomach discomfort. Other reactions reported include oral irritation and sensitization. Most adverse effects are typically mild and well-tolerated, even with prolonged therapy.

System-Organ Class Common Adverse Reactions (from clinical reports)
Gastrointestinal Disorders Diarrhea, nausea, vomiting, stomach upset/disturbances
General Disorders and Administration Site Conditions Oral irritation, sensitization

Serious Adverse Reactions and Safety Limitations

Serious Adverse Reactions that have been rarely reported include Stevens-Johnson syndrome and other severe dermatologic reactions, which are classified as extremely rare but serious. Hypersensitivity reactions, including facial swelling, bronchospasm, and rash, have been reported rarely and may require immediate medical attention.

Safety-Related Restrictions and Limitations:

  • Mikostat is contraindicated in patients with a known history of hypersensitivity to nystatin or any of its components.
  • It is explicitly stated that this medication is not indicated for the treatment of systemic mycoses (fungal infections in the lungs or skin).
  • Irritation or sensitization developing during treatment may necessitate discontinuation of the drug, according to regulatory cautions.

Population-Specific Safety Notes

  • Pregnancy: It is not known whether this drug can cause fetal harm when administered to a pregnant person. It should only be used if the potential benefit outweighs the potential risk.
  • Breast-feeding: It is unknown whether Mikostat is excreted in human milk. Caution should be exercised when the drug is prescribed to a person who is nursing.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Element Official Regulatory Statements
Documented overdose presentations Primarily gastrointestinal disturbances, including nausea, vomiting, and diarrhea.
Physiological systems affected Official labeling reports no systemic toxicity due to the drug's insignificant absorption; effects are localized to the gastrointestinal tract.
Dose-related or exposure-related factors Manifestations are generally associated with taking oral doses in excess of five million units daily.
Population-specific overdose notes Patients with renal insufficiency may occasionally develop significant plasma concentrations of Mikostat following oral therapy.
Emergency-response statements Seek professional assistance or contact a Poison Control Center immediately.
When immediate medical help is required Call emergency services (such as 911) if the victim has collapsed, has a seizure, or has trouble breathing.

Overdose Classifications (High-Level)

Element Official Regulatory Statements
Severity classification Classified by the absence of serious toxic effects and lack of systemic toxicity following overdosage.
Overdose-context constraints Management is defined as symptomatic and supportive treatment; no specific antidote is documented.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is primarily characterized by gastrointestinal upset, typically following doses exceeding the recommended daily limit.
  • Regulatory documentation affirms that no serious toxic effects have been reported due to the drug’s insignificant systemic absorption.
  • Management is limited to symptomatic and supportive care, as no specific antidote is available.
  • Immediate action is required for all suspected overdosages, including contacting a Poison Control Center.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define Mikostat's overdose profile as having a low systemic risk, consistent with its minimal absorption. This profile directs management toward supportive care for gastrointestinal symptoms, which are the main documented manifestation. Despite the low risk, regulators mandate immediate contact with professional assistance or emergency services if severe symptoms are present.

Therapeutic Uses of Mikostat

What Mikostat Treats: Main Uses and Benefits

Mikostat is a medicine used to support the management of fungal or yeast infections. It is commonly prescribed for a variety of candida-related conditions. The main indications include oral thrush (a fungal infection in the mouth), certain skin infections, and intestinal candidiasis. Using Mikostat is intended to relieve discomfort and symptoms such as soreness, irritation, or redness associated with the infection.

This medicine has roles in both treating current infections and in certain prevention protocols. Its therapeutic use is as an antifungal agent for infections caused by fungus or yeast.

“It is a medication that supports the control of fungal conditions.”


Quick Fact: Supportive management for fungal overgrowth

Eligibility and Restrictions for Use

Mikostat (Nystatin) eligibility is determined by specific rules outlined in official regulatory documents, focusing on the drug’s use as a localized antifungal.

Who Cannot Use Mikostat? (Contraindications)

The preparation is formally prohibited for use in:

  • Hypersensitivity: Patients with a documented history of allergy or hypersensitivity to the active ingredient (nystatin) or to any other component (excipient) of the specific drug formulation.
  • Systemic Infection: The medicine must not be used for the treatment of systemic mycoses (widespread, invasive fungal infections). Its use is strictly limited to localized infections.

Approved and Restricted Populations

Population Group Eligibility Status (Regulatory Basis)
Infants, Children, & Adults Approved. Oral suspension is indicated for use across all age groups, including premature and low birth weight infants.
Pregnant Women Conditional Use. Oral/topical forms are assigned an FDA Pregnancy Category C, meaning use is permitted only if clearly needed. Vaginal forms are generally permitted (Category A for some forms).
Nursing Mothers Conditional Use. Caution should be exercised. It is not known if nystatin is excreted in human milk, although negligible gastrointestinal absorption suggests minimal risk.
Children Under 5 Restricted Form. They should not use lozenges or pastilles due to safety concerns; oral suspension is the preferred and appropriate form.
Elderly Patients Use Not Established. Official labeling notes that clinical studies of some forms did not include sufficient numbers of subjects aged 65 and older to determine if responses differ from younger adults.

Eligibility is also restricted for individuals who are systemically unwell or who have rare hereditary problems with sugar intolerance, as the oral suspension contains sucrose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interaction information documented in official regulatory labeling for Mikostat (Nystatin).

Documented Interacting Products and Categories

Classification Interacting Agents or Product Categories Regulatory Status and Constraint
Biological Products Allogeneic cultured keratinocytes/fibroblasts in bovine collagen Contraindicated combination. Mikostat can degrade the biological product. A suitable wash-out period is required following exposure before application of the biological product.
Probiotics/Yeasts Saccharomyces boulardii (lyo), Brewer's Yeast Avoid Combination. The antifungal agent may decrease the effects of these live organisms. Alternate therapy should be considered.
Nephrotoxic Agents Voclosporin and similar agents with known nephrotoxicity/ototoxicity risk Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity. Therapy modification may be necessary.
Diagnostic Tests Coccidioidin skin test Potential for interference with test results is documented.

Summary of Interaction Constraints

The primary constraints for use of Mikostat revolve around its fungicidal and fungistatic action. The drug is contraindicated with specific biological products due to the risk of product degradation. Similarly, its use with certain yeasts and probiotics is officially documented as one to avoid, as the antifungal activity can reduce their effectiveness. Additionally, caution and close monitoring are required when co-administering Mikostat with agents that carry a risk of organ toxicity, such as nephrotoxicity or ototoxicity, due to the potential for additive toxic effects.

Mechanism of Action

Mechanistic Targeting of Ergosterol

Mikostat’s mechanism of action begins with its ability to selectively target ergosterol, a crucial structural lipid found exclusively in the plasma membrane of susceptible fungal cells. Unlike human cell membranes, which utilize cholesterol, the mechanism is based on targeting ergosterol. This targeted binding initiates the physical destruction of the fungal cell's outer barrier.


Membrane Permeabilization and Homeostasis Collapse

The drug molecules aggregate upon binding to form transmembrane pores (channels), fundamentally disrupting the Fungal Membrane Integrity Pathway. This process acts as an ionophore, causing the rapid, uncontrolled leakage of vital ions (like K^+) and essential cellular components. The physiological consequence is the collapse of the cell's electrochemical gradient and internal pressure, resulting in the loss of cellular viability.


Constrained Mechanistic Scope

Mikostat's mechanism is constrained to localized or peripheral pathways because the molecule exhibits minimal systemic absorption. Therefore, the membrane disruption and the resulting loss of fungal cellular viability occur solely at the **site of exposure.

Dosage and Administration Information

How to Use Mikostat

Mikostat is a medicine administered through highly specialized routes designed exclusively for localized action against fungal infections. The use pattern is determined by the specific formulation, which dictates whether the medicine acts on the oral mucosa, skin, or gastrointestinal tract.


Administration Routes and Standard Regimens

The medicine is supplied as an oral suspension for localized treatment of the mouth and throat, film-coated tablets for use in the intestines, topical preparations for skin infections, and vaginal tablets.

For oropharyngeal candidiasis in adults, the typical dosing involves 400,000 to 600,000 units per dose, administered four times daily. The topical forms are typically applied two to four times daily to the affected areas.


Procedural Conditions and Duration

The correct use of Mikostat requires maximizing the localized contact time with the infected tissue. The oral suspension must be shaken well before measurement and is instructed to be retained in the mouth as long as possible before swallowing, often after meals. Specific unit doses, such as 100,000 units four times daily, are designated for low birth weight infants, who should generally not be fed for five to ten minutes following administration.

Treatment duration is determined by the site of infection and must be completed, often requiring continuous use for a minimum of 48 hours after clinical signs subside in oral cases, or 14 consecutive days for intravaginal use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mikostat

Evidence for the Use in Localized Oral Candidiasis

Research for this indication includes Randomized Controlled Trials (RCTs) and Systematic Reviews that examined patient populations including infants, children, and older adults with oral candidiasis. Studies monitored outcomes related to physical discomfort and mycological clearance. Findings describe patterns related to clinical changes in lesions during short-term follow-up. Evidence remains limited by historical trials and follow-up durations.

Evidence for Use in Prophylaxis for High-Risk Infants

RCTs and Meta-Analyses explored the medicine's use for prevention in Very Low Birth Weight (VLBW) preterm infants in the NICU. Researchers monitored the rate of fungal colonization and the incidence of Invasive Fungal Infection (IFI). Studies report patterns of difference in colonization rates measured between the medicine group and controls. Long-term effects after hospital discharge are not fully established, and no significant difference was observed for systemic outcomes like mortality rates.

Evidence for Topical and Vaginal Localized Infections

Clinical trials and RCTs were conducted on formulations used for candidiasis of the skin and vagina in adults and children. Studies examined patient-reported outcomes describing perceived discomfort and mycological cure. Findings describe measurable clinical changes following short-term use. Many studies are historical, and there is limited modern comparative evidence against newer topical treatments.

Studies in Special and Specific Populations

Research included studies on older adults with denture-related candidiasis and immunocompromised patients. Findings in immunocompromised patients were mixed when measured against systemic antifungals. Data for certain groups remain limited, and subgroup findings are uncertain for complex patient populations.

Long-Term Evidence and Durability of Study Findings

The majority of research involves limited follow-up durations, typically only covering the treatment course itself. Long-term outcomes and information on recurrence rates are not fully established in the research, which means the available evidence provides context but not individual predictions about long-term symptom control.

Key Studies & References

  1. Nystatin Oral Suspension USP - DailyMed (FDA-published labeling information)
  2. Nystatin for the treatment of candidiasis in children and neonates (EMA Paediatric Investigation Plan assessment report data)
  3. A systematic review of the management of oral candidiasis associated with HIV/AIDS (Evidence for special populations)

Frequently Asked Questions (FAQ)

Common questions about Mikostat (FAQ)

Q: Why is Mikostat only available with a prescription?

A: Mikostat is officially classified as a Human Prescription Drug (Rx Only) by regulatory authorities. This status is required due to the nature of the active ingredient and the need for a professional clinical diagnosis. A prescription is necessary to ensure the medicine is used properly for confirmed localized fungal infections.


Q: What is the safety classification of Mikostat by major regulatory health bodies?

A: According to official product information, Mikostat is classified as a Human Prescription Drug (Rx Only). It is not listed as a Controlled Substance by major regulatory bodies, meaning it does not carry a DEA schedule classification.


Q: Is Mikostat considered a new or older type of medication?

A: Official product documents indicate that Mikostat is an established, older medication. Its active ingredient, nystatin, is classified as a polyene antibiotic and was historically derived from a natural source, Streptomyces noursei.


Q: What is the expected timeline to notice any effect from Mikostat?

A: Clinical studies indicate that initial symptom relief for localized oral infections is typically observed starting within 24 to 72 hours after the treatment regimen begins. The full resolution of the infection usually requires completing the full prescribed duration.


Q: Is Mikostat intended for short-term relief or long-term management?

A: Mikostat is generally prescribed for short-term use to clear an active fungal infection. However, regulatory information notes that the medicine may also be used for the prevention of infection (prophylaxis) in certain situations under clinical supervision.


Q: How long does Mikostat stay in the body after the last use?

A: Because Mikostat is minimally absorbed systemically, the majority of the medicine does not typically enter the bloodstream or circulate in the systemic body for an extended period. The medicine that is not absorbed at the site of infection is eliminated unchanged, primarily in the stool.


Q: How quickly does the body process and eliminate Mikostat?

A: Official pharmacokinetic data explains that gastrointestinal absorption of the medicine is insignificant. Because the drug works primarily through localized action, most orally administered medicine is passed and eliminated quickly, unchanged in the feces.


Q: Is it normal to experience increased fatigue when first starting Mikostat?

A: Fatigue is not listed as a reported side effect of the medicine itself in regulatory documents. The experience of fatigue is not documented as a side effect of the medicine itself. Any new or continuing concerning symptoms should be brought to the attention of a healthcare provider.


Q: Does taking Mikostat cause changes in appetite or body weight?

A: Adverse reactions documented in regulatory sources do include decreased appetite and stomach discomfort (such as bloating or upset). However, changes in overall body weight are not specifically listed as a known side effect of the medicine.


Q: What do official drug materials say about managing a missed dose of Mikostat?

A: Regulatory patient instructions describe the guidance for a missed dose: if a dose is missed, the recommended action is to take it as soon as the patient remembers. If it is almost time for the next scheduled dose, the guidance is to skip the missed dose entirely and not take a double dose.


Q: Does Mikostat interact with over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Official interaction checkers and clinical guidance generally find no direct interaction between Mikostat and common over-the-counter pain relievers. These include medications like ibuprofen or acetaminophen.


Q: How does Mikostat interact with alcohol consumption?

A: No specific interaction warnings regarding the consumption of alcoholic beverages are generally provided in regulatory documents. It is noted that the liquid suspension forms may contain a very small amount of alcohol (up to le 1% v/v) as an inactive ingredient.


Q: Does Mikostat affect or interact with birth control pills?

A: The medicine itself does not directly affect hormonal contraception. However, official patient advice notes that if Mikostat causes severe vomiting or diarrhea (which are documented side effects), the efficacy of oral contraceptive pills may potentially be reduced.


Q: How does Mikostat compare to other common treatments for the same condition?

A: Regulatory information notes that for treating oral fungal infections, other antifungals like miconazole or fluconazole may be prescribed. These options often differ from Mikostat in their systemic absorption (how much enters the bloodstream) and certain other pharmacological characteristics.


Q: Do studies suggest that the effectiveness of Mikostat decreases over extended periods of time?

A: Official microbiology data generally indicates that resistance to the active ingredient does not commonly develop in the body during use. However, regulatory information notes that long-term animal studies to evaluate potential carcinogenic (cancer-causing) effects have not been performed.


Q: Are there special considerations for elderly patients taking Mikostat?

A: The official documents note that because the drug is minimally absorbed, systemic side effects are unlikely to differ significantly in older patients. However, regulatory records also state that original clinical trials did not include a sufficient number of subjects aged 65 and over to fully assess their responses.


Q: Is Mikostat safe for people with pre-existing kidney or liver conditions?

A: The drug is generally not processed by the liver since it is minimally absorbed systemically. This is consistent with its characteristics of minimal systemic absorption and elimination primarily in the stool. However, regulatory warnings note that in patients with pre-existing renal insufficiency (poor kidney function), the drug may occasionally reach significant plasma concentrations.


Q: Does Mikostat have known interactions with common dietary supplements or vitamins?

A: Official guidance addresses interactions with certain live yeast supplements, but generally states there is not enough clinical data to confirm that all common dietary supplements, vitamins, or complementary medicines are safe to take at the same time. It is generally understood that complete medication lists, including all supplements, should be reviewed by a prescribing professional.

How should Mikostat be stored and disposed of?

Mikostat (Nystatin) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from freezing, light, and moisture.

Container and Protection

It is required to store Mikostat in its original, tightly closed container.

Storage Restriction Requirement
Temperature Do not freeze.
Environment Protect from light and moisture.
Child Safety Keep out of the reach of children.

Disposal

Unused or expired Mikostat should be disposed of according to local pharmaceutical waste regulations. The preferred method is using a drug take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and discarded with the household trash. It should not be flushed down a toilet unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mikostat found in:

A-Z Index: